TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Oragenics ( (OGEN) ).
Oragenics, Inc. has appointed Ms. Natasha Giordano to its Board of Directors, effective September 1, 2025. Ms. Giordano brings extensive experience in the pharmaceutical and healthcare industries, having held leadership roles in various companies, including PLx Pharma Inc. and Xanodyne Pharmaceuticals. Her appointment is expected to enhance Oragenics’ strategic direction and operational expertise.
Spark’s Take on OGEN Stock
According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.
Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.
To see Spark’s full report on OGEN stock, click here.
More about Oragenics
Average Trading Volume: 527,741
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.25M
See more data about OGEN stock on TipRanks’ Stock Analysis page.